South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Published:2018-12-17 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Barratt Shaney L.,Mulholland Sarah,Al Jbour Khaled,Steer Henry,Gutsche Markus,Foley Noeleen,Srivastava Rajiv,Sharp Charles,Adamali Huzaifa I.

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference32 articles.

1. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis.;Bonella;Respiration,2016

2. Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis.;Brunnemer;Respiration,2018

3. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP).;Costabel;Respiration,2017

4. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.;Cottin;Eur. Respir. Rev.,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-07-04

2. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease;Seminars in Arthritis and Rheumatism;2024-02

3. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK;ERJ Open Research;2024-01

4. The role of the clinical pharmacist in the respiratory or sleep multidisciplinary team;Breathe;2023-12

5. The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study;PLOS ONE;2023-09-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3